Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: GLP-1-Fc-FGF21, GLP-1/FGF21 Fc dual agonist, GLP-1-IgG4 Fc-FGF21
This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.
Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.
The descriptor refers to recombinant fusion proteins in which a GLP-1 receptor agonist domain and an FGF21 domain or variant are linked through an IgG4 Fc region. Reported constructs include GLP-1-Fc-FGF21 D1 and D3, which were designed as long-acting dual agonists. The exact amino-acid sequence, linker arrangement, Fc mutations, and FGF21 substitutions are not uniquely defined by the generic compound name.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Evidence is construct-specific and predominantly preclinical. In one study, GLP-1-Fc-FGF21 D1 was evaluated in mice at 1, 3, 10, and 20 nmol/kg with subcutaneous dosing twice weekly for four weeks; these are experimental animal-study parameters and are not generalized dosing recommendations. A separate clinical-trial record describes AP026/TQA2226 as a GLP-1-FGF21-Fc bifunctional fusion protein, but the available record does not establish that it is identical to the IgG4-Fc construct represented by this generic entry. No standardized catalog size, approved nonproprietary name, unique registry identifier, or sequence-defined identity was established for the generic descriptor.
Supplementary research context only. Not medical advice or a treatment recommendation.
Reported GLP-1-Fc-FGF21 D1 and D3 constructs had an observed molecular mass of approximately 103 kDa by SDS-PAGE and mass-spectrometric analysis. The reported D1 construct incorporated an engineered FGF21 variant with enhanced β-Klotho binding relative to the reference FGF21 construct. The generic descriptor should not be treated as a single sequence-defined molecular entity without an associated sequence or construct identifier.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention GLP-1/IgG4 Fc/FGF21 fusion protein or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.